Relay Therapeutics, Inc. (RLAY)
RLAYNASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$20.14
+1.29 (+6.84%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $4.51bn
- P/E
- –
- EPS, last 4 quarters
- $-1.51
- Dividend yield
- –
- Day range
- –
- 52-week range
- $5.95 to $21.27
- Average volume
- 2.99m
- Previous close
- $18.85
Analysts
8 coveringBuy8 buy, 0 hold, 0 sell
Targets a year out average $28.86, +43.3% from here
Earnings
next estimate $-0.3800Next report
Dec 2025
+15.8%
Mar 2026
-17.1%
Jun 2026
0.0%
Sep 2026
+7.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $7.00m | $3.00m | $350.0k | – |
| Gross profit | $7.00m | $3.00m | $350.0k | – |
| Operating income | -$60.63m | -$78.59m | -$90.82m | -$90.25m |
| Net income | -$54.89m | -$73.29m | -$83.71m | -$81.75m |
News
8 latest- Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?Zacks · Sep 24, 2026
- Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?Zacks · Sep 3, 2026
- Relay Therapeutics CFO Sells 17,717 Shares for $350,000The Motley Fool · Sep 2, 2026
- The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and AbsciZacks · Aug 18, 2026
- 4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes PharmaZacks · Aug 17, 2026
- Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue EstimatesZacks · Aug 6, 2026
- Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings EstimatesZacks · Aug 3, 2026
- Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?Zacks · Jul 30, 2026
The company
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics' Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company's lead clinical asset, zovegalisib, is the first pan-mutant selective PI3K inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3K-driven vascular anomalies. Relay Therapeutics' pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- relaytx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.